Indexa Markets Brief — Monday 30 March

3 stories · Sent Monday, 30 March 2026

Indexa

Morning Markets Brief

Monday, 30 March 2026

Today’s top story: Eli Lilly pays $115m upfront in $2.75bn AI drug deal with Insilico. 3 stories analysed across the financial press, with market implications.

M&A • 6 outlets

Eli Lilly pays $115m upfront in $2.75bn AI drug deal with Insilico

Eli Lilly has agreed a global R&D collaboration with Insilico Medicine, the Hong Kong-listed AI drug developer, under which Lilly receives an exclusive…

Why it matters: The $2.75bn deal, even at $115m upfront, sets a valuation comp for AI-native drug discovery platforms that reprices the entire sector. Recursion Pharmaceuticals, Schrodinger, and Exscientia are the…

Read full analysis →

Commodities • 6 outlets

Brent tops $115 as Houthis enter Iran conflict with strikes on Israel

Brent crude has risen above $115 a barrel, surging more than 3% after Yemen's Houthi rebels struck Israel over the weekend, widening a conflict now entering…

Why it matters: Houthi strikes on Israeli territory, not just Red Sea shipping lanes, shift market pricing from temporary disruption to sustained multi-front conflict. This removes the scenario where Hormuz and Gulf…

Read full analysis →

Regulation • 3 outlets

Bank of America to pay $72.5M to settle Epstein victims lawsuit

Bank of America has agreed to pay $72.5 million to settle a class-action lawsuit brought by women who allege they were victims of Jeffrey Epstein's sex…

Why it matters: The $72.5M settlement is immaterial to BAC's capital position but re-opens reputational and litigation discovery risk. Unlike JPMorgan and Deutsche Bank, which had direct banking relationships with…

Read full analysis →

This is an archived issue of the Indexa Morning Markets Brief.

Visit Indexa • Subscribe

← 29 Mar

Get this in your inbox every morning

The top financial stories of the day, with market implications and source analysis. Free forever.